Last reviewed · How we verify
Non-adjuvanted HSV formulation 1 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Non-adjuvanted HSV formulation 1 (Non-adjuvanted HSV formulation 1) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Non-adjuvanted HSV formulation 1 TARGET | Non-adjuvanted HSV formulation 1 | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Non-adjuvanted HSV formulation 1 CI watch — RSS
- Non-adjuvanted HSV formulation 1 CI watch — Atom
- Non-adjuvanted HSV formulation 1 CI watch — JSON
- Non-adjuvanted HSV formulation 1 alone — RSS
Cite this brief
Drug Landscape (2026). Non-adjuvanted HSV formulation 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/non-adjuvanted-hsv-formulation-1. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing